Is CRISPR Therapeutics AG halal to invest in?

According to Musaffa's Shariah screening methodology, CRISPR Therapeutics AG (CRSP) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is CRISPR Therapeutics AG a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CRISPR Therapeutics AG using these criteria to determine its compliance status.

Can Muslims buy shares of CRISPR Therapeutics AG?

Muslim investors may consider investing in CRISPR Therapeutics AG if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is CRISPR Therapeutics AG classified as NOT HALAL?

Musaffa determines the Shariah status of CRISPR Therapeutics AG by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for CRISPR Therapeutics AG updated?

The Shariah compliance status of CRISPR Therapeutics AG may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like CRISPR Therapeutics AG become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of CRISPR Therapeutics AG?

You can check the latest Shariah compliance status of CRISPR Therapeutics AG on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CRSP Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 11, 2026

Report Source: 2026 1st Quarter Report

CRISPR Therapeutics AG. Stock Analysis CRSP

United States Health Care Mid Cap Report: Q1, 2026

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Key Statistics of CRISPR Therapeutics AG (CRSP)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$48.25$50.45

Today's Open

$49.74

Volume

1.98M

P/E Ratio (TTM)

52 Week Range

$34.87$78.48

Market Cap

5.05B

Avg. Volume

1.81M

Dividend Yield

Financial Metrics & Statements of CRISPR Therapeutics AG (CRSP)

FAQ's for CRISPR Therapeutics AG (CRSP)

According to Musaffa’s Shariah screening methodology, CRISPR Therapeutics AG (CRSP) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.